FLT3 and acute myeloid leukemia: Gilteritinib, a selective FLT3 inhibitor, demonstrated superior overall survival compared to salvage chemotherapy in a phase III trial (ADMIRAL) involving relapsed/refractory FLT3-mutated AML patients [21].